Planned release dihydroergotamine in common migraine and "tension-vascular headache": multicentre clinical trial.

The antimigraine efficacy of dihydroergotamine methanesulphonate in the pharmaceutical form of planned release capsules has been evaluated. Forty-nine subjects were treated, 39 suffering from common migraine 10 from tension vascular headache, for a period of 90 days, with an oral dose of 15 mg twice daily. The product was found to be efficacious in 71% of the common migraine cases, while unsatisfactory or nil results were obtained in the remaining 29%.

[Symptomatic dementia syndrome of multiple sclerosis].

A clinical-pathological study is presented concerning a patient affected by a demential syndrome at a young age (32 years). The neurological examination of the patient disclosed an asymmetry of the deep reflexes and a pale optic disk in both eyes. The pathological examination showed a typical MS, with extensive involvement of the frontal lobes.